Title: Hemoglobinopathies Market size is expected to witness significant growth from 2016 to 2023
1Hemoglobinopathies Market Size, Industry Analysis
Report, Regional Outlook, Application Potential,
Price Trends, Competitive Market Share
Forecast, 2016 2023 Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
Low Power Wide Area Network
2Regional Analysis of Hemoglobinopathies Market
- Globally, incidence of thalassemia is about 0.2
million patients, whereas sickle cell anemia has
higher occurrence of around 20 million. - In 2015, North America was the largest revenue
generating region with around USD 1.2 billion
owing to rise in RD investments, better
compensation state, and presence of high quality
healthcare infrastructure. - Asia Pacific hemoglobinopathies market share is
anticipated to increase at 9 CAGR due to rising
patient awareness and introduction of
manufactured and low cost diagnostic kits. - Sickle cell anemia is the most prevalentdisease
in West Africa, with nearly 20 of people having
sickle cell trait and about 2 of total babies
born with a form of the disease. In many regions
of Europe, hemoglobin (Hb) disorders are
classified as prevalent diseases.
3Application Analysis of Hemoglobinopathies
Market
- Hemoglobinopathy is a group of inherited
disorders caused due to abnormal production or
aberration in hemoglobin structure. - Different disorders comprise sickle cell anemia,
S-C and hemoglobin C disorder and various forms
of thalassemia. - Originally found in the Mediterranean area and
large parts of Asia and Africa, they now have
presence across the globe on account of growing
migration. - Most common tools/tests for diagnosis of
hemoglobinopathies and thalassemia disorders are
pre-implantation genetic diagnosis, genetic and
blood testing, alkaline and acid gel
electrophoresis, hemoglobin electrophoresis,
prenatal genetic testing and HbA2 quantification
by ion exchange column chromatography.
4 Competitive Market Share of Hemoglobinopathies
Market
- Key industry players comprise Alnylam
Pharmaceuticals, Gamida Cell, Biogen Idec,
AcceleronPharma, Sangamo BioSciences, Anthera
Pharmaceuticals, Global Blood Therapeutics,
Genetix Pharmaceuticals, Mast Therapeutics,
Prolong Pharmaceuticals, Emmaus Medical, Calgene
Corporation, Invenux, Optinova Ab, and HemaQuest
Pharmaceuticals. - Companies are aiming on the partnership and
licensing deals for sharing the research and
development platform. In 2014, Sangamo
BioSciences and Biogen Idec declared
collaboration agreement that targeted
hemoglobinopathies market therapeutics
development.
5 Browse Full Market Research Report On
Hemoglobinopathies Market _at_ https//www.gminsights
.com/industry-analysis/hemoglobinopathies-market
Request for an in-depth table of contents for
this report _at_ https//www.gminsights.com/request-t
oc/upcoming/470
6Stay In Touch Website www.gminsights.com Soci
al Media